Trends & Forecasts

Neal Baer, editor of a collection of essays on CRISPR, says we must not overlook the dark side of the technology.

Experts explain why these are two important areas to watch in the near future of pharma R&D.

We take a deep dive into key industry trends off the back of Clarivate’s Drugs to Watch 2025 report

In part 2 of our roundtable discussion, thought leaders discuss what Trump could do for drug pricing and whether change is to be feared or embraced.

We speak with Clarivate about their report listing eleven key drugs to watch in 2025.

And getting the right people involved from the start. Here’s why collaboration is key for successful clinical development.

Biden pushed drug pricing reforms, whereas Trump is known for deregulation. What does this mean for pharma?

The Access to Medicine Foundation has developed the 2026 AMR Benchmark to recognize and promote urgency in the ongoing AMR challenge.

Not all patients are able to reap the benefits of groundbreaking new therapeutics. The industry must do more.

From gene therapy to novel excipients to trends in leadership and more. Check out some of our most popular videos.